Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase

Oncogenic FLT3 kinase is a clinically validated target in acute myeloid leukemia (AML), and both multi-targeted and selective FLT3 inhibitors have been developed. Spleen tyrosine kinase (SYK) has been shown to be activated and increased in FLT3-ITD-positive AML patients, and has further been shown t...

Descripción completa

Detalles Bibliográficos
Autores principales: Weisberg, Ellen L., Puissant, Alexandre, Stone, Richard, Sattler, Martin, Buhrlage, Sara J., Yang, Jing, Manley, Paul W., Meng, Chengcheng, Buonopane, Michael, Daley, John F., Lazo, Suzan, Wright, Renee, Weinstock, David M., Christie, Amanda L., Stegmaier, Kimberly, Griffin, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581010/
https://www.ncbi.nlm.nih.gov/pubmed/28881711
http://dx.doi.org/10.18632/oncotarget.19036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581010/
https://www.ncbi.nlm.nih.gov/pubmed/28881711
http://dx.doi.org/10.18632/oncotarget.19036

Ejemplares similares